Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | PDE9A | O76083 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HEXA | P06865 | 1/20 | 0.42 |
| ▸ | HEXB | P07686 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22119249 | 0.91 | PDE9A (0.42) | PDE9A | |
| SCHEMBL22119392 | 0.84 | PDE9A (0.43) | PDE9A | |
| SCHEMBL22119161 | 0.83 | — | — | |
| SCHEMBL32665812 | 0.83 | — | — | |
| SCHEMBL22245127 | 0.83 | TGFBR1 (0.47) | PDE9ABRD4 | |
| SCHEMBL22119586 | 0.81 | PDE9A (0.56) | PDE9ABRD4LMNA | |
| SCHEMBL22119175 | 0.81 | PDE9A (0.42) | PDE9A | |
| SCHEMBL22119052 | 0.81 | BCDIN3D (0.45) | — | |
| SCHEMBL22119185 | 0.81 | PDE9A (0.55) | PDE9AKMT2AMEN1BRD4LMNA | |
| SCHEMBL22119422 | 0.80 | NMT1 (0.43) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | ACURX PHARMACEUTICALS LLC (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3897645-A1 | DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF | Acurx Pharmaceuticals, LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020132174-A1 | DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF | ACURX PHARMACEUTICALS, LLC (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | GAA 129/4885PDE9A 2005/4885KMT2A 2290/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | GAA 2143/4885PDE9A 2788/4885KMT2A 2397/4885 |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | GAA 128/4885PDE9A 2025/4885KMT2A 2315/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | GAA 129/4885PDE9A 2005/4885KMT2A 2290/4885 |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | GAA 128/4885PDE9A 2025/4885KMT2A 2315/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | GAA 128/4885PDE9A 2025/4885KMT2A 2315/4885 |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | GAA 129/4885PDE9A 2005/4885KMT2A 2290/4885 |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | GAA 128/4885PDE9A 2025/4885KMT2A 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.